USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Positive results could propel the company into the top tier of immuno-oncology drugmakers, pharma’s fastest developing space, but a bad outcome could leave its status as a big pharma player in serious doubt. 12 June 2017
US immuno-oncology specialist NewLink Genetics lost 41% of its value on Thursday after Swiss pharma giant Roche’s Genentech unit handed back the rights to the cancer candidate GDC-0919 (navoximod). 9 June 2017
Mylan is fighting battles on multiple fronts, including over price increases of its EpiPen (epinephrine) devices and as it races to market with its biosimilar products. 7 June 2017
Chinese healthcare investment firms Frontline BioVentures and WuXi Healthcare Ventures are to merge, creating a venture capital giant with combined assets under management of 5.5 billion renminbi, or $800 million. 30 May 2017
Privately-held US biotech firm Palladio Biosciences has bought the global rights to lixivaptan from the American arm of Chiesi Farmaceutici. 24 May 2017
Taking in and making use of key findings from conferences can be a difficult task but industry veteran Shawn Manning, managing director of investment banking firm Outcome Capital, came away from this month’s BioTrinity 2017 in the UK with some important learnings on the life sciences sector at present. 22 May 2017
Belgian biotech Ablynx has completed the preparation of a pre-clinical package for the novel Nanobody, ALX-1141 in osteoarthritis, a milestone in its collaboration with Merck KGaA (MRK: DE). 22 May 2017
The shift of Swiss pharma giant Novartis towards the new-age end of biotech has been made evident in an announcement to cut 500 jobs and create 350 others. 19 May 2017
US healthcare giant Johnson & Johnson’s pharma unit Janssen expects more than 10 of its new ‘blockbuster’ products to be launched or filed for regulatory approval by 2021. 17 May 2017
French drugmaker Ipsen expects its annual sales to exceed 2.5 billion euros ($2.7 billion) in 2020, an increase of around 58% on its 2016 total of 1.58 million euros. 12 May 2017
Netherlands-incorporated Mylan has unveiled first quarter 2017 results indicating a 24% increase in revenue compared with the same period a year before. 10 May 2017
Valeant Pharmaceuticals International has had to endure a 95% reduction in its share price value in the last two years, but there was finally some encouraging news for investors as the company announced its latest quarterly results. 9 May 2017
There were positive aspects of Almirall’s first quarter financial results but investors are likely to have been most struck by a 10% drop in profits as the company’s share price fell by 4% to 15.93 euros in five hours of trading after the figures were announced on Monday. 8 May 2017
New York-based Ovid Therapeutics listed on the Nasdaq stock exchange today, pricing its initial public offering of 5 million shares at $15 each. After its first morning’s trading, the price had fallen about 10%. 5 May 2017
Danish diabetes giant Novo Nordisk saw its share price decline by a massive 36% in 2016, but the roots of recovery are evident after it reported its first-quarter results for 2017, sending shares up by 6% in five hours of trading on Wednesday to 281.60 Danish kroner. 3 May 2017
In a hard-hitting expert view piece, Dr Oded Ben-Joseph and Dr Shawn Manning, from investment bank Outcome Capital, advise on how life science companies can achieve shareholder objectives without falling into some common traps. 3 May 2017
Private company ImCheck Therapeutics has raised 20 million euros ($22 million) to fund research into antibodies involved in the immune system. 3 May 2017
US pharma giant Merck & Co has beaten estimates with its first quarter 2017 sales figures and has raised its revenue and earnings guidance for 2017. 2 May 2017
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news